Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5582097 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 7 Pages |
Abstract
Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor stage and folliculotropic mycosis fungoides.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker,